#1 Clinical Trials Search in Europe

Teriparatide

This article explores the use of teriparatide, a medication used to treat osteoporosis, in various clinical trials. Teriparatide, also known by brand names like Forteo and Forsteo, is a synthetic form of parathyroid hormone that stimulates new bone formation. The trials discussed here investigate its effectiveness, safety, and potential applications in different patient populations and treatment scenarios.

Table of Contents

What is Teriparatide?

Teriparatide is a medication used primarily for treating osteoporosis, a condition characterized by weak and fragile bones. It’s known by several names, including FORTEO, FORSTEO, and LY333334[1]. Teriparatide is unique among osteoporosis treatments because it’s the only drug that promotes the formation of new bone, rather than just preventing bone loss[2].

Teriparatide is actually a portion of the human parathyroid hormone (PTH). It’s created using recombinant DNA technology, which means it’s produced in a laboratory using genetic engineering techniques[3].

How Teriparatide Works

Unlike other osteoporosis medications that primarily prevent bone loss, teriparatide works by stimulating new bone formation. It does this by increasing the activity of osteoblasts, the cells responsible for building new bone[4]. This unique mechanism of action makes teriparatide particularly effective for people with severe osteoporosis or those at high risk of fractures.

When you take teriparatide, it increases the rate of bone formation, leading to increased bone mineral density (BMD). BMD is a measure of how much calcium and other minerals are present in a segment of bone. Higher BMD generally indicates stronger bones[1].

Conditions Treated with Teriparatide

Teriparatide is primarily used to treat:

  • Postmenopausal Osteoporosis: This is the most common use of teriparatide. It’s prescribed for women who have gone through menopause and are at high risk of bone fractures[3].
  • Osteoporosis in Men: Teriparatide is also approved for use in men with osteoporosis who are at high risk of fracture[4].
  • Glucocorticoid-Induced Osteoporosis: This is osteoporosis caused by long-term use of steroid medications like prednisone[5].

In some cases, teriparatide is also being studied for its potential to speed up the healing of fractures, particularly in older adults[6].

How Teriparatide is Administered

Teriparatide is typically administered as a daily injection under the skin (subcutaneous injection). The standard dose is 20 micrograms per day[3]. It’s usually prescribed for up to 24 months, as prolonged use may increase the risk of developing bone cancer (osteosarcoma) in animal studies, although this hasn’t been observed in humans[1].

Researchers are also exploring alternative methods of administration, including:

  • Nasal Spray: Some studies are investigating the possibility of delivering teriparatide through a nasal spray, which could be more convenient for patients[2].
  • Transdermal Patch: Another potential method being studied is a skin patch that would deliver the medication through the skin[7].

Effectiveness of Teriparatide

Teriparatide has been shown to be highly effective in treating osteoporosis and reducing the risk of fractures. Studies have demonstrated that it can:

  • Increase bone mineral density, particularly in the spine and hip[1].
  • Reduce the risk of vertebral (spine) and non-vertebral fractures[5].
  • Improve bone structure and strength, as measured by advanced imaging techniques[4].
  • Potentially speed up the healing of certain types of fractures[6].

It’s important to note that the effectiveness of teriparatide can vary from person to person, and your doctor will monitor your progress throughout the treatment.

Potential Side Effects

Like all medications, teriparatide can cause side effects. Common side effects may include:

  • Nausea
  • Dizziness
  • Leg cramps
  • Joint pain

Some patients may experience a temporary increase in blood calcium levels after injection. This is usually not harmful but should be monitored by your doctor[8].

As mentioned earlier, long-term use of teriparatide (beyond 2 years) is not recommended due to a potential risk of osteosarcoma observed in animal studies[1].

Ongoing Research and Future Developments

Researchers continue to study teriparatide to better understand its effects and explore new applications. Some areas of ongoing research include:

  • Fracture Healing: Studies are investigating whether teriparatide can speed up the healing of certain types of fractures, particularly in older adults[6].
  • Alternative Delivery Methods: As mentioned earlier, researchers are exploring nasal sprays and skin patches as potential alternatives to daily injections[2][7].
  • Combination Therapies: Some studies are looking at how teriparatide works when combined with other osteoporosis medications[9].
  • Long-term Effects: Researchers are studying the long-term effects of teriparatide treatment, including what happens after patients stop taking the medication[4].

These ongoing studies may lead to new uses for teriparatide or improvements in how it’s administered, potentially making it even more effective and convenient for patients in the future.

Aspect Details
Drug Name Teriparatide (also known as Forteo, Forsteo)
Primary Use Treatment of osteoporosis
Mechanism of Action Stimulates new bone formation
Administration Daily subcutaneous injection
Treatment Duration Typically up to 24 months
Key Outcomes Increased bone mineral density, reduced fracture risk
Patient Populations Postmenopausal women, men with osteoporosis
Ongoing Research Alternative delivery methods, use in fracture healing

FAQ

  • What is teriparatide and how does it work? Teriparatide is a synthetic form of parathyroid hormone used to treat osteoporosis. It works by stimulating new bone formation, unlike other osteoporosis medications that primarily prevent bone loss. Teriparatide is typically administered as a daily subcutaneous injection.
  • How effective is teriparatide in treating osteoporosis? Clinical trials have shown that teriparatide is effective in increasing bone mineral density (BMD) and reducing fracture risk in patients with osteoporosis. For example, one study found significant increases in lumbar spine BMD after 24 weeks of treatment.
  • Are there any side effects associated with teriparatide use? While teriparatide is generally well-tolerated, some patients may experience side effects such as nausea, dizziness, or leg cramps. It's important to discuss potential side effects with your healthcare provider.
  • How long can patients use teriparatide? Teriparatide is typically prescribed for up to 24 months. The duration of treatment is limited due to the potential risk of osteosarcoma observed in animal studies, although this risk has not been confirmed in humans.
  • Can teriparatide be used to treat other conditions besides osteoporosis? While primarily used for osteoporosis, some clinical trials are exploring the potential use of teriparatide in other conditions. For example, one study investigated its use in accelerating healing of ankle fractures in older adults.

Ongoing Clinical Trials on Teriparatide

  • Study on Treating Adynamic Bone Disorder with Teriparatide in Patients with Chronic Kidney Disease

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study Comparing Teriparatide and Alendronate for Preventing Bone Fractures in Women Over 65 with Fragile Bones

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Treating Osteogenesis Imperfecta in Patients Using Teriparatide and Zoledronic Acid

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Ireland The Netherlands

Glossary

  • Bone Mineral Density (BMD): A measure of the amount of minerals (usually calcium and phosphorus) contained in a certain volume of bone. BMD is used to diagnose osteoporosis and assess fracture risk.
  • Osteoporosis: A condition characterized by decreased bone mass and density, leading to an increased risk of fractures. It often occurs in postmenopausal women and older adults.
  • Parathyroid Hormone (PTH): A hormone produced by the parathyroid glands that regulates calcium levels in the body. Teriparatide is a synthetic form of a portion of this hormone.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Bone Turnover: The process by which old bone tissue is removed (resorption) and new bone tissue is formed. Teriparatide affects this process by stimulating new bone formation.
  • Fracture Risk: The likelihood of experiencing a bone fracture, often assessed using factors such as BMD, age, and previous fracture history.
  • Anabolic Therapy: A type of treatment that stimulates the formation of new bone tissue. Teriparatide is an example of an anabolic therapy for osteoporosis.
  • Biomarkers: Measurable indicators of biological processes. In osteoporosis treatment, biomarkers like P1NP and CTX are used to assess bone formation and resorption.

References

  1. https://clinicaltrials.gov/study/NCT00557310
  2. https://clinicaltrials.gov/study/NCT01913834
  3. https://clinicaltrials.gov/study/NCT00532545
  4. https://clinicaltrials.gov/study/NCT01155232
  5. https://clinicaltrials.gov/study/NCT01078805
  6. https://clinicaltrials.gov/study/NCT02955056
  7. https://clinicaltrials.gov/study/NCT00489918
  8. https://clinicaltrials.gov/study/NCT02656810
  9. https://clinicaltrials.gov/study/NCT03002428